Marshall Wace
MLYS icon

Marshall Wace’s Mineralys Therapeutics MLYS Stock Holding History

Marshall Wace’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$243K Sell
8,987
-240,143
-96% -$7.04M ﹤0.01% 2713
2025
Q4 		$9.04M Buy
+249,130
New +$9.99M 0.01% 917

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Marshall Wace's MLYS Position: Q1 2026 in Review

Marshall Wace reduced its Mineralys Therapeutics (MLYS) stake by 96% in Q1 2026, selling an estimated $7.04M and leaving 8,987 shares worth $243K. The position accounts for ﹤0.01% of the portfolio, ranked #2713.

Marshall Wace first reported a position in MLYS in Q4 2025 and has held it in 2 quarters since. The position peaked at $9.04M in Q4 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Marshall Wace held 8,987 shares of Mineralys Therapeutics worth $243K as of Q1 2026.
  • Marshall Wace sold 240,143 Mineralys Therapeutics shares in Q1 2026, an estimated $7.04M.
  • Mineralys Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2713 holding.
  • Marshall Wace first reported a position in Mineralys Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Marshall Wace's Mineralys Therapeutics position peaked at $9.04M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.